This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Teva fined EUR462.6 million for abusing patent system to defend MS drug

By Lewis Crofts ( October 31, 2024, 10:45 GMT | Insight) -- Teva Pharmaceuticals must pay a fine of 462.6 million euros for harming competition by hindering challengers to its blockbuster multiple sclerosis treatment. The European Commission sanctioned the company, saying it “artificially extended the patent protection of Copaxone and systematically spread misleading information about a competing product to hinder its market entry and uptake.” The case is the latest EU fine against pharma companies suspected of using the regulatory system for intellectual property to safeguard the market power of a successful drug.Teva Pharmaceuticals must pay a fine of 462.6 million euros for harming competition by hindering challengers to its blockbuster multiple sclerosis treatment....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections